Pharmaceutical Technology

FEBRUARY 19, 2024

Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.

Licensing 241

Licensing Licensing Antibody 241

Pharmaceutical Technology

APRIL 21, 2023

Twist Bioscience and Astellas Pharma have entered a collaboration to help the latter to discover antibodies for immunotherapies. In May 2022, they signed a research partnership and exclusive option licence agreement for the development of antibodies to reduce tumour microenvironment-mediated immunosuppression.

Antibody 264

Antibody Licensing Licensing Protein 264

Pharmaceutical Technology

MARCH 16, 2023

Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio. The MPN Technology provides an elegant way for delivering antibodies inside tumour cells.

Antibody 262

Antibody In-Vivo Pharma Companies Protein 262

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy. Immatics is one of the most important players concerning innovation surrounding cancer monoclonal antibody therapy.

Antibody 261

Antibody Immune Response Protein Development 261

Pharmaceutical Technology

AUGUST 24, 2023

Japan has granted a new drug substance patent for BioArctic’s monoclonal antibody (mAb), BAN0805, to treat Parkinson’s disease.

Antibody 245

Antibody Drugs 245

Pharmaceutical Technology

AUGUST 1, 2024

AbCellera Biologics has broadened its partnership with Eli Lilly to discover therapeutic antibodies for various diseases.

Antibody 130

Antibody 130

Bio Pharma Dive

MAY 7, 2024

The $200 million round is the latest evidence that surging interest in autoimmune disease cell therapies could expand to include developers of bispecific antibodies, too.

Antibody 177

Antibody Development 177

Pharmaceutical Technology

OCTOBER 21, 2022

AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

Antibody 217

Antibody Protein Licensing Licensing 217

Pharmaceutical Technology

OCTOBER 2, 2024

Focus is turning to the development of peptide analogs of antibody-derived radiotherapeutics, according to Dr. Dave Madge.

Antibody 130

Antibody Development 130

Pharmaceutical Technology

MAY 2, 2024

Discover how Agenus Inc's groundbreaking patent for antibodies targeting TIM-3 is revolutionizing therapeutic antibody development. Explore the specific amino acid sequences and methods for efficient antibody production.

Antibody 130

Antibody Production Development 130

Pharmaceutical Technology

MARCH 7, 2024

Gilead Sciences has entered an agreement with Merus for the discovery of dual tumour-associated antigens targeting trispecific antibodies.

Antibody 162

Antibody 162

Pharmaceutical Technology

AUGUST 28, 2024

Navigator Medicines has secured $100m in a Series A financing round with the aim of advancing bispecific antibody therapeutics.

Antibody 130

Antibody Medicine 130

Pharmaceutical Technology

JULY 21, 2022

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.

Antibody 264

Antibody Compliance Clinical Trials Clinical Trials 264

Pharmaceutical Technology

APRIL 4, 2024

Discover Xencor Inc's groundbreaking patent for novel GPC3 binding domains and bispecific antibodies targeting GPC3-associated cancers. Explore the innovative method for manufacturing these antibodies and their potential in cancer treatment.

Antibody 130

Antibody Manufacturing 130

Pharmaceutical Technology

JULY 25, 2024

Dren Bio has entered a strategic partnership with Novartis Pharma to develop therapeutic bispecific antibodies to treat cancer.

Antibody 130

Antibody Development 130

Pharmaceutical Technology

JANUARY 9, 2023

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.

FDA Approval 246

FDA Approval Antibody Clinical Trials Clinical Trials 246

Pharmaceutical Technology

MAY 8, 2024

Zenas signed a licencing deal for Asia-Pacific territories for the bispecific antibody, obexelimab, with Bristol Myers Squibb in September.

Antibody 130

Antibody 130

Pharmaceutical Technology

AUGUST 9, 2024

For an upfront payment of $700m, MSD will gain access to the CD3 and CD19-targeting bispecific antibody CN201.

Antibody 130

Antibody Marketing 130

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody 246

Antibody Vaccine Vaccination Dermatology 246

Pharmaceutical Technology

JUNE 10, 2024

Discover Vir Biotechnology's groundbreaking patent for a monoclonal antibody targeting Staphylococcus aureus infections. Learn how this innovative composition binds to key proteins for potential treatment.

Antibody 130

Antibody Protein 130

Bio Pharma Dive

JUNE 16, 2021

The biotech said it will seek an expanded FDA clearance after results from the RECOVERY trial showed its antibody can lower mortality among certain hospitalized COVID-19 patients.

Antibody 325

Antibody Trials 325

Pharmaceutical Technology

DECEMBER 22, 2023

Ono has signed an agreement with EVQLV to utilise its AI-powered antibody design engine for the development of new antibody drugs.

Antibody 130

Antibody Development Engineer Drugs 130

Pharmaceutical Technology

MAY 28, 2024

J&J has made its second dermatology deal this month, adding Numab’s bispecific antibody NM26 to its growing atopic dermatitis drug portfolio.

Antibody 130

Antibody Dermatology Drugs 130

Bio Pharma Dive

NOVEMBER 5, 2020

Fast antibody testing, however, is spotty. The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.

Antibody 300

Antibody Drugs 300

Pharmaceutical Technology

MAY 24, 2023

HBM’s wholly owned subsidiary Nona Biosciences has entered an agreement with OPKO Health’s ModeX Therapeutics for the discovery of antibodies. ModeX Therapeutics will gain access to the fully human Harbour Mice platforms of Nona Bioscience for integration into its MSTAR platform to expedite the monoclonal antibodies’ discovery.

Antibody 147

Antibody Clinical Development Development Research 147

Bio Pharma Dive

APRIL 21, 2023

A decision by the Supreme Court could have far-reaching effects on the lucrative market for antibody drugs, spurring responses from many of the industry’s top companies.

Antibody 189

Antibody Marketing Drugs 189

Bio Pharma Dive

NOVEMBER 9, 2020

The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact.

Antibody 334

Antibody Drugs 334

Bio Pharma Dive

JUNE 18, 2021

drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca.

Antibody 345

Antibody Drugs 345

Pharmaceutical Technology

APRIL 30, 2024

Discover a groundbreaking patent for treating CLEC12A positive cancer with bispecific antibodies. Learn about a unique dosing strategy to target cancer cells effectively while sparing hemopoietic stem cells.

Antibody 130

Antibody 130

Bio Pharma Dive

OCTOBER 18, 2024

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Antibody 269

Antibody Trials 269

Bio Pharma Dive

APRIL 19, 2021

Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests.

Antibody 335

Antibody Drugs Development 335

Pharmaceutical Technology

FEBRUARY 22, 2024

The company’s monoclonal antibody therapy, IO-202, has received its second orphan drug designation as a treatment for a blood cancer, CMML.

Antibody 130

Antibody Drugs 130

Pharmaceutical Technology

APRIL 18, 2024

Discover how Vir Biotechnology's patented multispecific antibodies target distinct Zika virus epitopes, neutralizing ZIKV infection. Explore the innovative potential for prophylaxis and treatment in this groundbreaking patent.

Antibody 130

Antibody 130

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.

Antibody 279

Antibody Genotype Development Licensing 279

Bio Pharma Dive

MAY 28, 2024

The deal is J&J’s second this month involving bispecific antibodies, which the company has prioritized to build its immune and cancer drug pipeline.

Antibody 130

Antibody Drugs 130

pharmaphorum

OCTOBER 7, 2024

The recent Mpox outbreak highlights the urgent need for new approaches to therapeutic antibody research. Discover how the World Health Organization (WHO) and CDC are responding to this public health crisis.

Antibody 111

Antibody Research 111

Pharmaceutical Technology

APRIL 10, 2024

Discover the groundbreaking patent by Kyowa Kirin Co Ltd for a monoclonal antibody targeting CCR1, inhibiting its activation by CCL15. Explore the therapeutic and diagnostic potential for CCR1-related diseases.

Antibody 130

Antibody 130